Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell Leukemia

The news of U.S. FDA approval of our oncology drug, Nelarabine Injection, is a hugely significant milestone for us at Shorla Oncology. Nelarabine Injection is a critical treatment for patients living with T-cell Leukemia, particularly for children with leukemia, and it is our hope that today’s approval addresses the clinical need in this patient community.

Read more at: